The GLP-1 Revolution — Everyone And Their Moms Are On GLP-1s

Q: How long will it take to read this news story?

The story "The GLP-1 Revolution — Everyone And Their Moms Are On GLP-1s" has 2727 words across 101 sentences, which will take approximately 12 - 23 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "The GLP-1 Revolution — Everyone And Their Moms Are On GLP-1s" was covered 21 hours ago by Forbes, a news publisher based in United States.

Q: How trustworthy is 'Forbes' news outlet?

Forbes is a fully independent (privately-owned) news outlet established in 1917 that covers mostly startups and technology news. The outlet is headquartered in United States and publishes an average of 15 news stories per day. It's most recent story was published 13 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #26448173</li><li>URL: https://chronographically.beamstart.com/news/the-glp-1-revolution-17405358506457</li></ul>

Forbes Logo Forbes 21h ago

The GLP-1 Revolution — Everyone And Their Moms Are On GLP-1s - Forbes

Quick Summary:

Most patients don’t stop taking the GLP-1 drugs because the weight they lose will return if they stop taking the drugs.

Upscale gym chains including Equinox and Life Time have rolled out strength-focused training plans for members on GLP-1 drugs to combat muscle loss; Life Time launched a “performance and longevity” subscription program that includes a in-gym clinic with doctors who can prescribe GLP-1 drugs when appropriate, metabolic blood testing, meetings with a dietitian, and personal training.

Betting on a widespread GLP-1 adoption, some private equity investors are practicing an investor version of the ‘Ozempic diet’ and are refraining from investing in consumer companies (such as snackmakers, alcohol brands, or restaurant chains) that could be negatively impacted by the GLP-1 boom, believing that profits will get squeezed as GLP-1 users no longer crave them and/or obesity rates fall."Even if the types of foods don’t change for someone on a drug like Ozempic, the amount of consumption usually does," one PE investor explains to Axios.